KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Amortizatization of Intangibles: 2014-2025

Historic Amortizatization of Intangibles for Sarepta Therapeutics (SRPT) over the last 8 years, with Sep 2025 value amounting to -$1.1 million.

  • Sarepta Therapeutics' Amortizatization of Intangibles rose 89.33% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.7 million, marking a year-over-year increase of 74.97%. This contributed to the annual value of -$40.3 million for FY2024, which is 12.78% up from last year.
  • Sarepta Therapeutics' Amortizatization of Intangibles amounted to -$1.1 million in Q3 2025, which was up 39.28% from -$1.9 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Amortizatization of Intangibles high stood at -$50,000 for Q1 2022, and its period low was -$13.3 million during Q4 2023.
  • Its 3-year average for Amortizatization of Intangibles is -$8.3 million, with a median of -$10.5 million in 2024.
  • As far as peak fluctuations go, Sarepta Therapeutics' Amortizatization of Intangibles plummeted by 17,202.00% in 2023, and later skyrocketed by 89.33% in 2025.
  • Sarepta Therapeutics' Amortizatization of Intangibles (Quarterly) stood at -$6.1 million in 2022, then slumped by 117.33% to -$13.3 million in 2023, then spiked by 48.96% to -$6.8 million in 2024, then skyrocketed by 89.33% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$1.9 million for Q2 2025, and -$1.9 million during Q1 2025.